COCP
NASDAQ · Pharmaceuticals
Cocrystal Pharma Inc
$1.03
-0.06 (-5.50%)
Financial Highlights (FY 2025)
Revenue
2.74M
Net Income
504.5K
Gross Margin
43.3%
Profit Margin
18.4%
Rev Growth
+19.3%
D/E Ratio
0.92
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 43.3% | 43.3% | 43.3% |
| Operating Margin | 26.7% | 27.6% | 26.8% |
| Profit Margin | 18.4% | 23.9% | 18.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.74M | 2.80M | 3.00M |
| Gross Profit | 1.19M | 1.21M | 1.30M |
| Operating Income | 732.3K | 775.0K | 806.0K |
| Net Income | 504.5K | 668.5K | 544.9K |
| Gross Margin | 43.3% | 43.3% | 43.3% |
| Operating Margin | 26.7% | 27.6% | 26.8% |
| Profit Margin | 18.4% | 23.9% | 18.1% |
| Rev Growth | +19.3% | -9.2% | +14.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.57M | 4.61M | 4.63M |
| Total Equity | 4.98M | 4.99M | 5.80M |
| D/E Ratio | 0.92 | 0.92 | 0.80 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 921.2K | 997.7K | 969.2K |
| Free Cash Flow | 728.8K | 746.2K | 561.0K |